Search
anti-OX40 antibody BMS 986178
go.drugbank.com/drugs/DB15773InvestigationalA macrocyclic peptide (BMS-986189) with activity in binding and functional assays comparable to a PD-L1 antibody.
Rifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawn[L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801]
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesEteplirsen
go.drugbank.com/drugs/DB06014ApprovedInvestigational[L40015] Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle deterioration and premature death most commonly due to respiratory or cardiac complications. … [A244930] It is caused by loss-of-function mutations in the DMD gene coding for dystrophin, an essential protein involved in maintaining the structural integrity and function of muscle fibres.
Synonyms: (P-deoxy-P-(dimethylamino)](2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a→5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G),5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonylTremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigational[A253717, L43652] Because CTLA-4 is an immune checkpoint that plays a vital role in regulating T cell-mediated immune response, tremelimumab is considered an immune checkpoint inhibitor, which is an emerging … [A253717, A253722] After receiving an EMA Committee for Medicinal Products for Human Use (CHMP) recommendation in December 2022, tremelimumab was approved for combined use with [durvalumab].[L46188]
Regorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalRegorafenib is an orally-administered inhibitor of multiple kinases.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesGuaiacol
go.drugbank.com/drugs/DB11359ApprovedGuaiacol is an agent thought to have disinfectant properties and used as an expectorant. Guaiacol is a phenolic natural product first isolated from Guaiac resin and the oxidation of lignin.
Liraglutide
go.drugbank.com/drugs/DB06655ApprovedInvestigationalVictoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine fo...
Perospirone
go.drugbank.com/drugs/DB08922InvestigationalPerospirone is an atypical or second-generation antipsychotic of the azapirone family that antagonizes serotonin 5HT2A receptors and dopamine D2 receptors.
Categories: Dopamine D2 Receptor Antagonists, Cytochrome P-450 SubstratesRosiglitazone
go.drugbank.com/drugs/DB00412ApprovedInvestigationalRosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. … Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersSynonyms: (±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedioneEfmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalIt is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It is suitable for all age groups. … In animal models of haemophilia, efmoroctocog alfa demonstrated an approximately two-fold longer t½ than commercially available rFVIII products [A31551].